Tor W Jensen1, Tania Ray1, Jinhua Wang1, Xiaodong Li1, Wesley Y Naritoku1, Bingchen Han1, Frank Bellafiore1, Sanjay P Bagaria1, Annie Qu1, Xiaojiang Cui1, Clive R Taylor1, Partha S Ray2. 1. : Interdisciplinary Health Sciences Initiative (TWJ, PSR), Department of Statistics (AQ), Beckman Institute for Advanced Science and Technology (PSR), University of Illinois Cancer Center (PSR), and Department of Surgery, University of Illinois College of Medicine (PSR), University of Illinois at Urbana Champaign, Urbana Champaign, IL; Onconostic Technologies, Inc., Champaign, IL (TR); John Wayne Cancer Institute, Santa Monica, CA (JW); Department of Pathology and Laboratory Medicine, Keck USC/LAC and USC Medical Center/VAGLAHS, Los Angeles, CA (XL, WYN); Departments of Surgery and Obstetrics and Gynecology, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BH, XC); Department of Pathology, Carle Foundation Hospital, Urbana, IL (FB); Department of Surgery, Mayo Clinic, Jacksonville, FL (SPB); Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CRT); Division of Surgical Oncology, Carle Cancer Center, Urbana, IL (PSR). 2. : Interdisciplinary Health Sciences Initiative (TWJ, PSR), Department of Statistics (AQ), Beckman Institute for Advanced Science and Technology (PSR), University of Illinois Cancer Center (PSR), and Department of Surgery, University of Illinois College of Medicine (PSR), University of Illinois at Urbana Champaign, Urbana Champaign, IL; Onconostic Technologies, Inc., Champaign, IL (TR); John Wayne Cancer Institute, Santa Monica, CA (JW); Department of Pathology and Laboratory Medicine, Keck USC/LAC and USC Medical Center/VAGLAHS, Los Angeles, CA (XL, WYN); Departments of Surgery and Obstetrics and Gynecology, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BH, XC); Department of Pathology, Carle Foundation Hospital, Urbana, IL (FB); Department of Surgery, Mayo Clinic, Jacksonville, FL (SPB); Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CRT); Division of Surgical Oncology, Carle Cancer Center, Urbana, IL (PSR). psray@illinois.edu.
Abstract
BACKGROUND: Diagnosis of basal-like breast cancer (BLBC) remains a bottleneck to conducting effective clinical trials for this aggressive subtype. We postulated that elevated expression of Forkhead Box transcription factor C1 (FOXC1) is a simple and accurate diagnostic biomarker for BLBC. METHODS: Accuracy of FOXC1 expression in identifying BLBC was compared with the PAM50 gene expression panel in gene expression microarray (GEM) (n = 1992) and quantitative real-time polymerase chain reaction (qRT-PCR) (n = 349) datasets. A FOXC1-based immunohistochemical (IHC) assay was developed and assessed in 96 archival formalin-fixed, paraffin-embedded (FFPE) breast cancer samples that also underwent PAM50 profiling. All statistical tests were two-sided. RESULTS: A FOXC1-based two-tier assay (IHC +/- qRT-PCR) accurately identified BLBC (AUC = 0.88) in an independent cohort of FFPE samples, validating the accuracy of FOXC1-defined BLBC in GEM (AUC = 0.90) and qRT-PCR (AUC = 0.88) studies, when compared with platform-specific PAM50-defined BLBC. The hazard ratio (HR) for disease-specific survival in patients having FOXC1-defined BLBC was 1.71 (95% CI = 1.31 to 2.23, P < .001), comparable to PAM50 assay-defined BLBC (HR = 1.74, 95% CI = 1.40 to 2.17, P < .001). FOXC1 expression also predicted the development of brain metastasis. Importantly, unlike triple-negative or Core Basal IHC definitions, a FOXC1-based definition is able to identify BLBC in both ER+ and HER2+ patients. CONCLUSION: A FOXC1-based two-tier assay, by virtue of being rapid, simple, accurate, and cost-effective may emerge as the diagnostic assay of choice for BLBC. Such a test could substantially improve clinical trial enrichment of BLBC patients and accelerate the identification of effective chemotherapeutic options for this aggressive disease.
BACKGROUND: Diagnosis of basal-like breast cancer (BLBC) remains a bottleneck to conducting effective clinical trials for this aggressive subtype. We postulated that elevated expression of Forkhead Box transcription factor C1 (FOXC1) is a simple and accurate diagnostic biomarker for BLBC. METHODS: Accuracy of FOXC1 expression in identifying BLBC was compared with the PAM50 gene expression panel in gene expression microarray (GEM) (n = 1992) and quantitative real-time polymerase chain reaction (qRT-PCR) (n = 349) datasets. A FOXC1-based immunohistochemical (IHC) assay was developed and assessed in 96 archival formalin-fixed, paraffin-embedded (FFPE) breast cancer samples that also underwent PAM50 profiling. All statistical tests were two-sided. RESULTS: A FOXC1-based two-tier assay (IHC +/- qRT-PCR) accurately identified BLBC (AUC = 0.88) in an independent cohort of FFPE samples, validating the accuracy of FOXC1-defined BLBC in GEM (AUC = 0.90) and qRT-PCR (AUC = 0.88) studies, when compared with platform-specific PAM50-defined BLBC. The hazard ratio (HR) for disease-specific survival in patients having FOXC1-defined BLBC was 1.71 (95% CI = 1.31 to 2.23, P < .001), comparable to PAM50 assay-defined BLBC (HR = 1.74, 95% CI = 1.40 to 2.17, P < .001). FOXC1 expression also predicted the development of brain metastasis. Importantly, unlike triple-negative or Core Basal IHC definitions, a FOXC1-based definition is able to identify BLBC in both ER+ and HER2+ patients. CONCLUSION: A FOXC1-based two-tier assay, by virtue of being rapid, simple, accurate, and cost-effective may emerge as the diagnostic assay of choice for BLBC. Such a test could substantially improve clinical trial enrichment of BLBC patients and accelerate the identification of effective chemotherapeutic options for this aggressive disease.
Authors: T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale Journal: Proc Natl Acad Sci U S A Date: 2001-09-11 Impact factor: 11.205
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou Journal: Clin Cancer Res Date: 2004-08-15 Impact factor: 12.531
Authors: Jennifer R Won; Dongxia Gao; Christine Chow; Jinjin Cheng; Sherman Y H Lau; Matthew J Ellis; Charles M Perou; Philip S Bernard; Torsten O Nielsen Journal: Mod Pathol Date: 2013-05-24 Impact factor: 7.842
Authors: H Goulding; S Pinder; P Cannon; D Pearson; R Nicholson; D Snead; J Bell; C W Elston; J F Robertson; R W Blamey Journal: Hum Pathol Date: 1995-03 Impact factor: 3.466
Authors: Marc J van de Vijver; Yudong D He; Laura J van't Veer; Hongyue Dai; Augustinus A M Hart; Dorien W Voskuil; George J Schreiber; Johannes L Peterse; Chris Roberts; Matthew J Marton; Mark Parrish; Douwe Atsma; Anke Witteveen; Annuska Glas; Leonie Delahaye; Tony van der Velde; Harry Bartelink; Sjoerd Rodenhuis; Emiel T Rutgers; Stephen H Friend; René Bernards Journal: N Engl J Med Date: 2002-12-19 Impact factor: 91.245
Authors: Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet Journal: Ann Intern Med Date: 2003-01-07 Impact factor: 25.391
Authors: Patrycja Gazinska; Anita Grigoriadis; John P Brown; Rosemary R Millis; Anca Mera; Cheryl E Gillett; Lars H Holmberg; Andrew N Tutt; Sarah E Pinder Journal: Mod Pathol Date: 2013-02-08 Impact factor: 7.842